These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 14684344)

  • 1. (2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors.
    Vaisburg A; Bernstein N; Frechette S; Allan M; Abou-Khalil E; Leit S; Moradei O; Bouchain G; Wang J; Woo SH; Fournel M; Yan PT; Trachy-Bourget MC; Kalita A; Beaulieu C; Li Z; MacLeod AR; Besterman JM; Delorme D
    Bioorg Med Chem Lett; 2004 Jan; 14(1):283-7. PubMed ID: 14684344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-keto amides as inhibitors of histone deacetylase.
    Wada CK; Frey RR; Ji Z; Curtin ML; Garland RB; Holms JH; Li J; Pease LJ; Guo J; Glaser KB; Marcotte PA; Richardson PL; Murphy SS; Bouska JJ; Tapang P; Magoc TJ; Albert DH; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2003 Oct; 13(19):3331-5. PubMed ID: 12951120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-(2-Amino-phenyl)-4-(heteroarylmethyl)-benzamides as new histone deacetylase inhibitors.
    Vaisburg A; Paquin I; Bernstein N; Frechette S; Gaudette F; Leit S; Moradei O; Raeppel S; Zhou N; Bouchain G; Woo SH; Jin Z; Gillespie J; Wang J; Fournel M; Yan PT; Trachy-Bourget MC; Robert MF; Lu A; Yuk J; Rahil J; Macleod AR; Besterman JM; Li Z; Delorme D
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6729-33. PubMed ID: 17977726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors.
    Moradei O; Leit S; Zhou N; Fréchette S; Paquin I; Raeppel S; Gaudette F; Bouchain G; Woo SH; Vaisburg A; Fournel M; Kalita A; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Li Z; Rahil J; MacLeod AR; Besterman JM; Delorme D
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4048-52. PubMed ID: 16713259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential protein acetylation induced by novel histone deacetylase inhibitors.
    Glaser KB; Li J; Pease LJ; Staver MJ; Marcotte PA; Guo J; Frey RR; Garland RB; Heyman HR; Wada CK; Vasudevan A; Michaelides MR; Davidsen SK; Curtin ML
    Biochem Biophys Res Commun; 2004 Dec; 325(3):683-90. PubMed ID: 15541343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase.
    Marson CM; Mahadevan T; Dines J; Sengmany S; Morrell JM; Alao JP; Joel SP; Vigushin DM; Charles Coombes R
    Bioorg Med Chem Lett; 2007 Jan; 17(1):136-41. PubMed ID: 17046252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors.
    Anandan SK; Ward JS; Brokx RD; Bray MR; Patel DV; Xiao XX
    Bioorg Med Chem Lett; 2005 Apr; 15(8):1969-72. PubMed ID: 15808449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, structural characterization and biological evaluation of N-protected cyclopropylethylcarbamates as potential histone deacetylase inhibitor.
    Jung JC; Moon HI; Oh S
    Chem Biol Drug Des; 2008 Dec; 72(6):592-5. PubMed ID: 19090926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indole amide hydroxamic acids as potent inhibitors of histone deacetylases.
    Dai Y; Guo Y; Guo J; Pease LJ; Li J; Marcotte PA; Glaser KB; Tapang P; Albert DH; Richardson PL; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1897-901. PubMed ID: 12749893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice.
    Joung KE; Min KN; An JY; Kim DK; Kong G; Sheen YY
    Cancer Res; 2006 May; 66(10):5394-402. PubMed ID: 16707467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
    Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
    Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
    Yoshida M; Shimazu T; Matsuyama A
    Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
    Andrianov V; Gailite V; Lola D; Loza E; Semenikhina V; Kalvinsh I; Finn P; Petersen KD; Ritchie JW; Khan N; Tumber A; Collins LS; Vadlamudi SM; Björkling F; Sehested M
    Eur J Med Chem; 2009 Mar; 44(3):1067-85. PubMed ID: 18672316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
    Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
    Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors.
    Fréchette S; Leit S; Woo SH; Lapointe G; Jeannotte G; Moradei O; Paquin I; Bouchain G; Raeppel S; Gaudette F; Zhou N; Vaisburg A; Fournel M; Yan PT; Trachy-Bourget MC; Kalita A; Robert MF; Lu A; Rahil J; Robert Macleod A; Besterman JM; Li Z; Delorme D
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1502-6. PubMed ID: 18207391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A series of novel, potent, and selective histone deacetylase inhibitors.
    Jones P; Altamura S; Chakravarty PK; Cecchetti O; De Francesco R; Gallinari P; Ingenito R; Meinke PT; Petrocchi A; Rowley M; Scarpelli R; Serafini S; Steinkühler C
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5948-52. PubMed ID: 16987657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations.
    Mai A; Valente S; Nebbioso A; Simeoni S; Ragno R; Massa S; Brosch G; De Bellis F; Manzo F; Altucci L
    Int J Biochem Cell Biol; 2009 Jan; 41(1):235-47. PubMed ID: 18834955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
    Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
    Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
    Suzuki N; Suzuki T; Ota Y; Nakano T; Kurihara M; Okuda H; Yamori T; Tsumoto H; Nakagawa H; Miyata N
    J Med Chem; 2009 May; 52(9):2909-22. PubMed ID: 19419205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.